Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (NCT06129734)
Phase 1B/2A Study of Weekly Decitabine and Venetoclax Treatment as Maintenance Therapy in High-Risk Myeloid Malignancy Patients Post Allograft Stem Cell Transplant
🩺 Plain-English Summary (8th-Grade Level)
The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy will help control leftover cancer with minimal side effects. This treatment involves decitabine and venetoclax. Participants will receive standard post-transplant care. Participants will be administered decitabine once per week with normal transplant follow up visits, and then will take a venetoclax pill about 6 to 8 hours later. Participants will meet their study team at the beginning, midway, and at the end of the trial to receive bone marrow testing. Participants will receive treatment until either one year of therapy, relapse, or recurrent dose limiting toxicity (DLT) despite dose reduction.
Who can join: Review the eligibility criteria below.
Location: Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
- University Hospitals Seidman Cancer, Case Comprehensive Cancer Center — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (216) 844-0139
Email: Benjamin.tomlinson@uhhospitals.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myeloid Malignancy
- Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms — Boston, Massachusetts
- Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories — Rochester, New York
- Pre-myeloid Cancer and Bone Marrow Failure Clinic Study — Scottsdale, Arizona
- Germline Testing for Predisposition to Myeloid Malignancies — Boston, Massachusetts
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies — Birmingham, Alabama
- A Telehealth Advance Care Planning Intervention — Rochester, New York
Explore by condition: All Myeloid Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.